NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
Arousal and stability - The effects of five new sympathomimetic drugs suggest a new principle for the prevention of space motion sicknessSympathomimetic agents are frequent components in antimotion-sickness drug combinations because of their usefulness in counteracting the sedation caused by stressful motion or resulting from the administration of other antimotion-sickness drugs. The noradrenergic neurochemistry of the brain's arousal-attentional systems prompted us to evaluate the efficacy of five new sympathomimetic drugs and to further define the role of arousal in susceptibility to motion. Subjects were orally administered methamphetamine (20 mg), phenmetrazine (25 mg), phentermine (37.5 mg), methylphenidate (20 mg), or pemoline (75 mg) 2 h prior to taking a Staircase Profile Test. All of the drugs increased resistance to stressful coriolis stimulation by 80-120 percent. Methylphenidate and pemoline showed fewer side effects. These findings, interpreted in conjunction with the documented inefficacy of most anticholinergic and antihistaminergic drugs tested to date, suggest that sympathomimetic drugs or a generalized state of arosusal can inhibit the development of motion sickness.
Document ID
19860040918
Acquisition Source
Legacy CDMS
Document Type
Reprint (Version printed in journal)
Authors
Kohl, R. L.
(NASA Johnson Space Center; Universities Space Research Association, Houston, TX, United States)
Calkins, D. S.
(NASA Johnson Space Center; Technology Inc. Houston, TX, United States)
Mandell, A. J.
(California, University La Jolla, United States)
Date Acquired
August 12, 2013
Publication Date
February 1, 1986
Publication Information
Publication: Aviation, Space, and Environmental Medicine
Volume: 57
ISSN: 0095-6562
Subject Category
Aerospace Medicine
Accession Number
86A25656
Distribution Limits
Public
Copyright
Other

Available Downloads

There are no available downloads for this record.
No Preview Available